Teva Presents New Tardive Dyskinesia Data At Psych Congress 2024 From The IMPACT-TD Registry, Revealing Differences In Patient Experience Based On Underlying Psychiatric Condition; Registry Revealed Fewer Patients With Psychotic Disorders (36%) Received TD Diagnoses Compared To Those With Mood Disorders (50%)
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceuticals presented new data at the Psych Congress 2024 from the IMPACT-TD Registry, highlighting differences in tardive dyskinesia (TD) patient experiences based on psychiatric conditions. The study found fewer TD diagnoses in patients with psychotic disorders compared to those with mood disorders. Teva continues to innovate in mental health treatment with AUSTEDO® XR® and AUSTEDO tablets.
November 01, 2024 | 7:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva Pharmaceuticals presented new data from the IMPACT-TD Registry at the Psych Congress 2024, showing differences in TD patient experiences based on psychiatric conditions. This highlights Teva's ongoing innovation in mental health treatments with AUSTEDO® XR® and AUSTEDO tablets.
The presentation of new data at a major congress demonstrates Teva's commitment to advancing mental health treatments, which could positively influence investor sentiment and potentially boost the stock price. The focus on AUSTEDO products suggests potential revenue growth.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90